These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35134041)

  • 1. Molnupiravir for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):10-11. PubMed ID: 35134041
    [No Abstract]   [Full Text] [Related]  

  • 2. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Audio Interview: A Potential New Agent to Treat Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(26):e101. PubMed ID: 34936745
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of COVID-19 in high-risk outpatients.
    Med Lett Drugs Ther; 2022 Feb; 64(1643):e1. PubMed ID: 35134051
    [No Abstract]   [Full Text] [Related]  

  • 8. Lethal mutagenesis as an antiviral strategy.
    Swanstrom R; Schinazi RF
    Science; 2022 Feb; 375(6580):497-498. PubMed ID: 35113690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
    Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
    Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 11. Buyer beware: molnupiravir may damage DNA.
    van Schalkwyk JM
    BMJ; 2021 Nov; 375():n2663. PubMed ID: 34737196
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study.
    Abu Ahmad W; Arbel R; Wolff Sagy Y; Battat E; Sergienko R; Friger M; Yaron S; Serby D; Zucker R; Hammerman A; Duskin Bitan H; Peretz A; Lavie G; Netzer D
    Clin Microbiol Infect; 2024 Oct; 30(10):1305-1311. PubMed ID: 38942382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on: Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients.
    Chen IW; Chang LC; Hung KC
    J Antimicrob Chemother; 2024 Jul; 79(7):1717-1718. PubMed ID: 38723108
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 17. Molnupiravir: First Approval.
    Syed YY
    Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir for the Treatment of Coronavirus Disease 2019: A Systematic Review With Meta-Analysis of 12,451 Patients.
    Beran A; Mhanna A; Mhanna M; Farrow D; Sidiki S; Khader Y; Srour O; Kayyali A
    Am J Ther; 2024 Jan-Feb 01; 31(1):e47-e50. PubMed ID: 38231582
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Immun Inflamm Dis; 2024 Apr; 12(4):e1262. PubMed ID: 38652021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.